What the study found
RNA polymerase I (Pol I) is a specialized enzyme that transcribes ribosomal DNA into precursor rRNA, starting ribosome biogenesis and supporting cell growth, metabolism, and proliferation. The review says recent studies have shown unique structural and regulatory features of Pol I, and that Pol I dysfunction is linked to cancer, ribosomopathies, leukodystrophies, neurodegenerative disorders, genome stability, immune regulation, and host-pathogen interactions.
Why the authors say this matters
The authors conclude that fundamental discoveries about Pol I are informing targeted interventions across oncology, neurodegeneration, developmental disorders, infection, and aging. They also note that small-molecule inhibitors and peptide-based approaches are expanding strategies to modulate Pol I activity.
What the researchers tested
This is a review article that integrates structural, mechanistic, and disease-focused studies on Pol I transcription. It summarizes how Pol I is regulated by signaling pathways, epigenetic mechanisms, and chromatin structure, and it surveys therapeutic approaches aimed at changing Pol I activity.
What worked and what didn't
The abstract reports that Pol I hyperactivation is a hallmark of cancer. It also states that loss-of-function mutations in Pol I cause ribosomopathies, leukodystrophies, and neurodegenerative disorders through nucleolar stress. The review says targeted therapies are emerging, but it does not compare specific treatments or give outcome data.
What to keep in mind
This abstract is a review summary, not a report of one new experiment, so it does not provide original data or detailed methods. It also does not state limitations, study size, or which therapeutic approaches are most effective.
Key points
- Pol I transcribes ribosomal DNA into precursor rRNA and helps start ribosome biogenesis.
- The review says Pol I is regulated by signaling pathways, epigenetic mechanisms, and chromatin structure.
- Pol I dysregulation is associated with cancer, ribosomopathies, leukodystrophies, and neurodegenerative disorders.
- The abstract notes that small-molecule inhibitors and peptide-based approaches are being developed to modulate Pol I activity.
- The review also links Pol I to genome stability, immune regulation, and host-pathogen interactions.
Disclosure
- Research title:
- Pol I transcription is linked to health, disease, and targeted therapy
- Publication date:
- 2026-02-23
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with peer-reviewed research without reading academic papers — one filtered digest, every Friday.